Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM
Status:
Not yet recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of combination of
Chidamide-Lenalidomine-Dexamethasone in relapsed or refractory multiple myeloma patients